Eurobio Scientific Benelux
0424.732.712 · rovalta.com · 22/09/2026
NORMAL SITUATION
Eurobio Scientific Benelux
Financial year 2025 · closed on 23/10/2025
Net result
-19,9 k €
+15.1% YoY
Gross margin
-10,9 k €
-74.2% YoY
Equity
174,3 k €
-10.3% YoY
Company — Normal situation.
Overview
What does Eurobio Scientific Benelux do?
Eurobio Scientific Benelux is a company registered in Belgium.
Legal situation
● Normal situation
BCE/KBO no. / VAT
BE 0424.732.712
Legal form
Public limited company
Contributed capital
413 258,34 €
Latest accounts
23/10/2025
Signals
Solid equity
Available with a Rovalta subscriptionTry for 7 days
Financials
Trend over 20 financial years
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||||||||||||||||||||||||||||||
| Gross margin | -10,9 k € | -74.2% | -6,2 k € | +23.0% | -8,1 k € | +84.0% | -50,8 k € | -39.2% | -36,5 k € | -1017% | 4 k € | -95.0% | 79,6 k € | -12.6% | 91 k € | -4.7% | 95,5 k € | -26.8% | 130,5 k € | +54.7% | 84,3 k € | -17.0% | 101,7 k € | -9.6% | 112,5 k € | -7.4% | 121,5 k € | +148% | 49 k € | +57.9% | 31 k € | +171% | 11,4 k € | -67.2% | 34,8 k € | -13.4% | 40,2 k € | -15.3% | 47,5 k € |
| EBITDA | -11,7 k € | -71.8% | -6,8 k € | +23.8% | -8,9 k € | +90.0% | -89 k € | -142% | -36,8 k € | -1114% | 3,6 k € | -95.4% | 79,2 k € | -12.6% | 90,7 k € | -4.7% | 95,2 k € | -26.8% | 130 k € | +54.8% | 84 k € | -17.1% | 101,3 k € | -9.6% | 112,1 k € | -7.5% | 121,1 k € | +150% | 48,4 k € | +59.0% | 30,4 k € | +607% | 4,3 k € | -87.4% | 34,1 k € | -7.8% | 37 k € | +145% | -82,2 k € |
| Operating result | -11,7 k € | -71.8% | -6,8 k € | +23.8% | -8,9 k € | +90.0% | -89 k € | -142% | -36,8 k € | -1114% | 3,6 k € | -95.4% | 79,2 k € | -12.6% | 90,7 k € | -4.7% | 95,2 k € | -6.1% | 101,3 k € | +574% | 15 k € | -53.5% | 32,4 k € | -25.0% | 43,2 k € | -17.3% | 52,2 k € | +539% | 8,2 k € | -73.2% | 30,4 k € | +215% | 9,7 k € | -66.4% | 28,7 k € | -22.3% | 37 k € | +141% | -90,1 k € |
| Net result | -19,9 k € | +15.1% | -23,5 k € | +7.0% | -25,2 k € | +74.5% | -99 k € | -165% | -37,4 k € | -1655% | 2,4 k € | -95.7% | 55,4 k € | -29.5% | 78,5 k € | -17.2% | 94,8 k € | +1.1% | 93,7 k € | +1854% | 4,8 k € | -77.7% | 21,6 k € | -24.0% | 28,4 k € | -14.9% | 33,3 k € | +52.5% | 21,9 k € | -32.8% | 32,5 k € | +980% | 3 k € | -77.3% | 13,3 k € | +33.5% | 9,9 k € | +103% | -288,9 k € |
| Balance sheet | |||||||||||||||||||||||||||||||||||||||
| Equity | 174,3 k € | -10.3% | 194,2 k € | -10.8% | 217,6 k € | -10.4% | 242,9 k € | -29.0% | 341,9 k € | -9.9% | 379,3 k € | +0.6% | 376,9 k € | +17.2% | 321,5 k € | +32.3% | 243,1 k € | +63.9% | 148,3 k € | +172% | 54,6 k € | +9.6% | 49,8 k € | +76.3% | 28,2 k € | +21297% | -133,2 € | +99.6% | -33,5 k € | +39.5% | -55,3 k € | +37.0% | -87,9 k € | +3.3% | -90,9 k € | +12.7% | -104,1 k € | +8.7% | -114,1 k € |
| Total assets | 174,3 k € | -95.0% | 3,5 M € | -0.1% | 3,5 M € | -0.4% | 3,5 M € | +887% | 357,3 k € | -21.3% | 454 k € | -0.9% | 458,1 k € | +11.4% | 411,2 k € | +41.8% | 290 k € | +44.4% | 200,8 k € | -49.9% | 401 k € | +12.6% | 356 k € | +9.7% | 324,5 k € | -42.3% | 562,1 k € | +20.1% | 468,2 k € | +140% | 194,7 k € | -44.4% | 350,3 k € | +53.1% | 228,9 k € | -3.8% | 238 k € | -13.8% | 276 k € |
| Cash | 1,9 k € | -79.8% | 9,2 k € | -11.5% | 10,4 k € | -85.5% | 72,1 k € | -49.1% | 141,7 k € | -40.6% | 238,4 k € | +52.1% | 156,7 k € | +79.7% | 87,2 k € | -65.9% | 255,4 k € | +33.2% | 191,8 k € | -26.9% | 262,3 k € | +54.1% | 170,2 k € | +66.3% | 102,4 k € | -24.4% | 135,4 k € | +132% | 58,5 k € | +1245% | 4,3 k € | +302% | 1,1 k € | -57.5% | 2,5 k € | -61.5% | 6,6 k € | – | |
| Debts | – | 3,3 M € | +0.2% | 3,3 M € | -0.1% | 3,3 M € | +21075% | 15,4 k € | -79.3% | 74,7 k € | -8.1% | 81,2 k € | -9.4% | 89,7 k € | +91.3% | 46,9 k € | -10.6% | 52,4 k € | -84.0% | 326,9 k € | +10.3% | 296,4 k € | +5.2% | 281,8 k € | -48.1% | 543,4 k € | +8.3% | 501,6 k € | +102% | 248,7 k € | -40.9% | 421,2 k € | +45.3% | 289,8 k € | -7.3% | 312,8 k € | -5.1% | 329,7 k € | |
| Other | |||||||||||||||||||||||||||||||||||||||
| Workforce | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 2,5 ETP | |||||||||||||||||||
Governance
Board of directors
Seen on filing of 23/10/2025 · 2 active · 45 ended
Active mandates
Eurobio Scientific SA
ActiveHervé Duchesne De Lamotte
ActiveEnded mandates
DIAXONHIT SA
EndedEUROBIO SCIENTIFIC SA
EndedHervé DUCHESNE DELAMOTTE
EndedDIAXONHIT SA
EndedFinancials
Annual accounts
Full financial information
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Type of account | Abridged model | Abridged model | Abridged model | Abridged model | Abridged model | Abridged model |
| Start of the financial year | 01/01/2025 | 01/01/2024 | 01/01/2023 | 01/01/2022 | 01/01/2021 | 01/01/2020 |
| Closing of the financial year | 23/10/2025 | 31/12/2024 | 31/12/2023 | 31/12/2022 | 31/12/2021 | 31/12/2020 |
| Length of the financial year | 10 months | 12 months | 12 months | 12 months | 12 months | 12 months |
| Filing date | 12/11/2025 | 05/06/2025 | 13/06/2024 | 16/06/2023 | 30/08/2022 | 22/07/2021 |
| General meeting | 23/10/2025 | 16/05/2025 | 17/05/2024 | 19/05/2023 | 27/05/2022 | 28/05/2021 |
| Currency of the financial year | EUR | EUR | EUR | EUR | EUR | EUR |
| NBB quality label | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls |
Ratios
Financial ratios
Looking for more information about this company?
Try for 7 daysFilings
Annual accounts filings
42 filings with the NBB
| Model | Closing | General meeting | Filed | Language | Document |
|---|---|---|---|---|---|
| Abridged model | 23/10/2025 | 23/10/2025 | 12/11/2025 | Dutch | |
| Abridged model | 31/12/2024 | 16/05/2025 | 05/06/2025 | Dutch | |
| Abridged model | 31/12/2023 | 17/05/2024 | 13/06/2024 | Dutch | |
| Abridged model | 31/12/2022 | 19/05/2023 | 16/06/2023 | Dutch | |
| Abridged model | 31/12/2021 | 27/05/2022 | 30/08/2022 | French | |
| Abridged model | 31/12/2020 | 28/05/2021 | 22/07/2021 | French | |
| Abridged model | 31/12/2019 | 29/05/2020 | 19/06/2020 | French | |
| Abridged model | 31/12/2018 | 31/05/2019 | 21/06/2019 | French | |
| Abridged model | 31/12/2017 | 25/05/2018 | 07/08/2018 | French | |
| Abridged model | 31/12/2016 | 26/05/2017 | 21/08/2017 | French | |
| Abridged model | 31/12/2015 | 27/05/2016 | 10/06/2016 | French | |
| Abridged model | 31/12/2014 | 29/05/2015 | 05/08/2015 | French | |
| Abridged model | 31/12/2013 | 30/05/2014 | 08/07/2014 | French | |
| Abridged model | 31/12/2012 | 31/05/2013 | 31/05/2013 | French | |
| Abridged model | 31/12/2011 | 25/05/2012 | 06/06/2012 | French | |
| Abridged model | 31/12/2010 | 27/05/2011 | 07/06/2011 | French | |
| Abridged model | 31/12/2009 | 28/05/2010 | 31/05/2010 | French | |
| Abridged model | 31/12/2008 | 29/05/2009 | 02/06/2009 | French | |
| Abridged model | 31/12/2007 | 30/05/2008 | 13/06/2008 | French | |
| Abridged model | 31/12/2006 | 25/05/2007 | 21/06/2007 | French | |
| Abridged model | 31/12/2005 | 26/05/2006 | 24/08/2006 | French | |
| Abridged model | 31/12/2004 | 01/06/2005 | 15/07/2005 | French | |
| Abridged model | 31/12/2003 | 09/06/2004 | 20/10/2004 | French | |
| Abridged model | 31/12/2002 | 12/06/2003 | 28/08/2003 | French |
Valuation
Estimate
Indicative valuation
The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.
Disclaimer
Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.
Directors & structure
Governance
Board of directors
Seen on filing of 23/10/2025 · 2 active · 45 ended
Active mandates
Eurobio Scientific SA
ActiveHervé Duchesne De Lamotte
ActiveEnded mandates
DIAXONHIT SA
EndedEUROBIO SCIENTIFIC SA
EndedHervé DUCHESNE DELAMOTTE
EndedDIAXONHIT SA
EndedShareholders
Ownership and network
Looking for more information about this company?
Try for 7 daysPublications
Belgian Official Gazette
Belgian Official Gazette publications
- Dissolution05/12/2025BUITENGEWONE ALGEMENE VERGADERING — ONTBINDING EN
- Restructuring03/07/2024Fusievoorstel
- Mandates26/06/2024Benoeming commissaris
- Other27/01/2023STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, )
- Registered office27/12/2022SIEGE SOCIAL
- Mandates08/07/2022STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, ) - DENOMINATION - OBJET - DEMISSIONS, NOMINATIONS
- Mandates05/11/2018DEMISSIONS, NOMINATIONS
- Mandates18/09/2017DEMISSIONS, NOMINATIONS
Source: Belgian Official Gazette
Similar companies
Competition
Similar companies
A company's peers, by sector and size, are included in the Business plan.
See the Business planTimeline
Timeline
- 2025Annual accounts 2025-19,9 k €↑
- 2024Annual accounts 2024-23,5 k €↑
- 2023Annual accounts 2023-25,2 k €↑
- 2022Annual accounts 2022-99 k €↓
- 2022Name changeEurobio Scientific Benelux
- 2021Annual accounts 2021-37,4 k €↓
- 2021Name changeGAMMA
- 2020Annual accounts 20202,4 k €↓
- 2019Annual accounts 201955,4 k €↓
- 2018Annual accounts 201878,5 k €↓
- 2017Annual accounts 201794,8 k €↑
- 2016Annual accounts 201693,7 k €↑
- 2015Annual accounts 20154,8 k €↓
- 2014Annual accounts 201421,6 k €↓
- 2013Annual accounts 201328,4 k €↓
- 2012Annual accounts 201233,3 k €↑
- 2011Annual accounts 201121,9 k €↓
- 2010Annual accounts 201032,5 k €↑
- 2009Annual accounts 20093 k €↓
- 2008Annual accounts 200813,3 k €↑
- 2007Annual accounts 20079,9 k €↑
- 2006Annual accounts 2006-288,9 k €